Респираторная медицина. Руководство (в 2-х томах) - Чучалин А. Г. - Страница 310

193.Gelder CM, Thomas PS, Yates DH, et al: Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction. Thorax 1995; 50:1033-1037.

194.Dupont LJ, Demedts MG, Verleden GM: Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 123:751-756, 2003.

195.Jatakanon A, Uasuf C, Maziak W, et al: Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160:1532-1539, 1999.

196.А.Г.Чучалин. Бронхиальная астма. Агар, 1997. Бронхиальная астма у взрослых. Атопический дерматит. Под редакцией А.Г.Чучалина. Атмосфера, 2002.

197.Бронхиальная астма у взрослых. Атопический дерматит. Под редакцией А.Г.Чучалина. Атмосфера, 2002.

198.Глобальная стратегия лечения и профилактики бронхиальной астмы. Пер. с англ. яз. Под ред. А.Г.Чучалина. Атмосфера, 2007.

199.Lange P, Parner J, Vestbo J, et al: A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339:1194-1200, 1998.

200.Woodruff PW, Khashayar R, Lazarus SC, et al: Relationship between airway inflammation, hyper-responsiveness and obstruction in asthma. J Allergy Clin Immunol 108:753-758, 2001.

201.Bennett WD, Brown JS, Zeman KL, et al: Targeting delivery of aerosols to different lung regions. J Aerosol Med 2002; 15:179-188.

202.Weber EJ, Levitt MA, Covington JK, Gambrioli E: Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm: A randomized, controlled trial. Chest 1999; 115:937-944.

203.Barnes PJ: Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998; 102:531-538.

204.Adcock IM, Ito K: Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis 2000; 55:256-266.

205.Boushey HA: Relationship of asthma severity to fatalities. In: Sheffer AL, ed. Fatal Asthma, New York: Marcel Dekker; 1998:363-385.

206.NAEPP : Executive Summary of the NAEPP Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma: Update on Selected Topics, Bethesda, MD, NIH, 2002.

207.Toogood JH, Baskerville J, Jennings B, et al: Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84:688-700.

208.Szefler S, Weiss S, Tonascia J: Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343:1054-1063.

209.Agertoft L, Pedersen S: Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343:1064-1069.

210.Devillier P, Baccard N, Advenier C: Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I. Synthesis, receptors and role of leukotrienes in asthma. Pharmacol Res 1999; 40:3-13.

211.Ducharme FM: Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: Systematic review of current evidence. BMJ 2003; 326:621.

212.Wechsler ME, Finn D, Gunawardena D, et al: Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117:708-713.

213.Barnes PJ: Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003; 167:813-818.

214.Ito K, Lim S, Caramori G, et al: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002; 99:8921-8926.

215.Leung DY, Sampson HA, Yunginger JW, et al: Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986-993.

216.Boushey HA: New and exploratory therapies for asthma. Chest 2003; 123(Suppl 3):439S-445S.

217.Simon HU, Grotzer M, Nikolaizik WH, et al: High altitude climate therapy reduces peripheral blood T lymphocyte activation, eosinophilia, and bronchial obstruction in children with house-dust mite allergic asthma. Pediatr Pulmonol 1994; 17:304-311.

218.Platts-Mills TAE, Mitchell EB, Nock P, et al: Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet 1982; 2:675-678.

219.Bjornsdottir US, Jakobinudottir S, Runarsdottir V, Juliusson S: The effect of reducing levels of cat allergen (Fel d 1) on clinical symptoms in patients with cat allergy. Ann Allergy Asthma Immunol 2003; 91:189-194.

220.Woodcock A, Forster L, Matthews E, et al: Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med 2003; 349:225-236.

221.Campbell D, DeKruyff RH, Umetsu DT: Allergen immunotherapy: Novel approaches in the management of allergic diseases and asthma. Clin Immunol 2000; 97:193-202.

222.Tighe H, Takabayashi K, Schwartz D, et al: Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 106:124-134, 2000.

223.Cox G, Miller JD, McWilliams A, et al: Bronchial thermoplasty for asthma. Am J Respir Crit Care Med 173:965-969, 2006.

224.Rowe BH, Bota GW, Fabris L, Therrien SA: Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: A randomized controlled trial. JAMA 1999; 281:2119-2126.

225.Edmonds ML, Camargo Jr CA, Brenner BE, Rowe BH: Replacement of oral corticosteroids with inhaled corticosteroids in the treatment of acute asthma following emergency department discharge: A meta-analysis. Chest 2002; 121:1798-1805.

226.National Institutes of Health/National Heart Lung and Blood Institute (NHLBI): Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention; NHLBI/WHO Workshop Report March 1993. NIH Publication No. 95 - 3659, Bethesda, MD, National Heart, Lung, and Blood Institute, 1995.

227.National Heart, Lung, and Blood Institute : Guidelines for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Program. Vol 2, No. 7, Bethesda, MD: NHLBI, NIH; 1997:1.8 - 9.

228.Greening AP, Ind PW, Northfield M, Shaw G: Treatment of adult asthmatic patients symptomatic on low dose inhaled corticosteroids: A comparison of the addition of salmeterol to existing inhaled corticosteroid therapy, with increasing the dose of inhaled corticosteroids. Lancet 1994; 344:219-224.

229.Rand CS, Wise RA, Nides M, et al: Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992; 146:1559-1564.

230.Liou A, Grubb JR, Schechtman KB, Hamilos DL: Causative and contributive factors to asthma severity and patterns of medication use in patients seeking specialized asthma care. Chest 2003; 124:1781-1788.

231.Slavin RG: Asthma and sinusitis. J Allergy Clin Immunol 90:534-537, 1992.

232.Harding SM, Richter JE: The role of gastroesophageal reflux in chronic cough and asthma. Chest 1997; 111:1389-1402.

233.Szefler SJ, Eigen H: Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109:730-742.

234.Bousquet J, Ben-Joseph R, Messonnier M, et al: A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 2002; 24:1-20.

235.McIvor RA, Pizzichini E, Turner MO, et al: Potential masking effects of salmeterol on airway infalmmation in asthma. Am J Respir Crit Care Med 1998; 158:924-930.

236.Lazarus SC, Boushey HA, Fahy JV, et al: Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial. JAMA 2001; 285:2583-2593.

237.O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al: Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1392-1397.